Update on Country Funding and Portfolio Optimization

48th Board Meeting
GF/B48/14
15-17 November 2022, Geneva, Switzerland
Table of contents

1. Update on Country Funding: 2020-2022 allocation period
2. Update on Portfolio Optimization and UQD: 2020-2022 allocation period
3. Preparations for 2023-2025 allocation period
Country Funding: virtually all 2020-2022 allocation now in implementation

Key messages:

• US$12.62 billion in Allocation funding (99%) has been Board-approved. 266 allocation-based grants now in implementation.

• US$341.5 million in Catalytic matching funds (100%) has been Board-approved. Integrated into 77 allocation-based grants now in implementation.

• US$224 million in Catalytic multicountry funds (97%) has been Board-approved. 14 catalytic multicountry grants now in implementation.
Funding request review and recommendation by TRP

195 out of 207 Funding Requests reviewed in Windows 1-7 have been recommended for grant-making, with a 6% iteration rate.

Reviews completed (94% recommended after first submission)

Source: GOS as of 14 October 2022
Allocation under review, by TRP window

Window 7 was the final TRP review window for the 2020-2022 funding cycle. All funding requests have been reviewed and recommended for grant-making.

Source: GOS as of 14 October 2022

Allocation amount is based on TRP recommended amount, requested amount, or program split.

HIV/AIDS
Tuberculosis
TB/HIV
Malaria
Multi-Component
Standalone RSSH
Multicountry
Iteration
Allocation recommended by GAC

As of mid-October 2022 the GAC has reviewed and recommended a total of US$12.62 billion in allocation funds, representing 99% of the 2020-2022 allocation. All US$12.62 billion is now integrated into Board-approved grants. 100% of catalytic matching funds (US$341.5 million) and 97% of catalytic multicountry funds (US$224 million) have also been GAC recommended and integrated into Board-approved grants.

Source: GOS as of 14 October 2022.
Amount is based on agreed program split (if available) or communicated allocation. Includes extensions.
Grants Board-approved and pending approval

164 grants were Board-approved by end-2020, and 93 new grants were additionally Board-approved in 2021. As of mid-October 2022, 21 grants have been Board-approved in 2022. 5 new grants remain to be reviewed and approved in 2022.

Source: GOS as of 14 October 2022
Anticipated registration based on 2017-2019 IP end dates. Registrations subject to change.
Allocation funding: at mid-October 2022

US$12.71 billion was available for country allocations, of which US$12.62 billion (99%) was integrated into Board-approved grants by mid-October 2022.

* Communicated amounts do not include funds for one country for which the allocation letter is still pending. For multi-component grants, amounts are split between diseases on the basis of program split. Since available funding per component may shift due to program split adjustments, grant amounts within component are not expected to sum to 100%.
### Matching Funds: at mid-October 2022

All the US$341.5 (100%) million designated for Matching Funds was integrated into Board-approved grants by mid-October 2022.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>150</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>41</td>
<td>10</td>
</tr>
<tr>
<td>56</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: GOS as of 14 October 2022
Multicountry Funds: at mid-October 2022

Of the US$230 million designated for Multicountry Funds, US$224 million (97%) was integrated into Board-approved grants by mid-October 2022.

Source: GOS as of 14 October 2022
US$100M was made available in October 2021 by the AFC to finance unfunded quality demand through Portfolio Optimization (GF/AFC17/DP03). In July 2022, a further US$150M was made available (GF/AFC19/DP03).

Out of these funds, certain high priority strategic and operational investment decisions were made through GAC and/or Board decision. These included:

- **US$12M for TB and HIV needs in Venezuela** approved under GF/B46/EDP02 for non-eligible countries in crisis in October 2021 (GF/SC17/18)
- **US$30M for Emergency Fund** (March 2022, GF/B46/EDP17)
- **US$40M for Emergency Fund** (October 2022, GF/B47/EDP17)
- **US$4M awarded for investments to strengthen sustainability and address transition challenges** in
  - Paraguay TB US$610,911 - GF/B46/EDP10
  - Romania TB EUR1,737,261 - GF/B46/EDP10
  - Albania TB/HIV US$1,547,119 – GF/B46/EDP22

  Certain urgent needs, requiring immediate investment decisions and financial commitments in order to accommodate longer lead times, were advanced with an executive GAC decision to prioritize gaps in malaria (ITN); TB (diagnosis); and urgent ARVs needs to prevent stock outs in Q1 2023 (US$96M). Per standard practice, these awards are subject to GAC review (including Partner inputs) and Board review and approval of the additional funding revision.
2020-2022 Unfunded Quality Demand

To date the TRP has approved US$5.96 billion in UQD for the 2020-2022 allocation period. US$5.6 billion remains on the UQD Register as of mid-October 2022.

Source: UQD Register as of 14 October 2022
Preparations for 2023-2025 allocation period

Key messages:

• Funding Request forms, instructions, and applicant guidance were published as planned in July 2022. Change coordination activities are underway. Allocation letters are expected to be sent out in December 2022.

• New Global Fund Strategy messages have been integrated into funding request materials, guidance and change coordination.

• Due to the increased ambition in the strategy, Funding Request requirements are more substantive than in the last cycle. For example, the number of documents and data requested in annexes has increased by 33% (from 14 to 21) to incorporate new topics and tools including: RSSH Gaps and Priorities, Community and Civil Society Priorities, Human Rights, Gender, Program Essentials, Country Dialogue, and Preventing Sexual Exploitation, Abuse and Harassment.

• As 66% of the allocation-based grants have an end-date of December 2023 we know that the peak of funding request submissions will be in the first half of 2023, and the peak of grant submissions and Board approvals will be in the second half of 2023.
2023-2025 Allocation Period Timeline

Legend
- FR application materials
- Allocation letters
- FR submission and review
- Grant-making
- Grant Implementation
- Board Meetings
- Replenishment Conference

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Q4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Preparation of FR templates, instructions, guidance materials (2022 Q1)
- Published application materials (July 2022)
- E-learnings/Webinars/Trainings (Sept-Dec 2022)
- Allocation letters (Dec 2022)
- Funding Request Submissions (from March 2023) + TRP review windows
- Grant-making activities
- Grant Implementation
## Published Resources

Available on the [Global Fund website](#)

### Already Available
- Funding Request Forms, Annexes, Instructions
- Modular Framework Handbook
- Guidance on CCM Eligibility Requirements 1 & 2
- Frequently Asked Questions
- Core Information Notes (HIV, TB, Malaria, RSSH)
- Technical Briefs & Guidance Notes
  - Guidance for Sustainability & Transition Planning for TB/HIV
  - Procurement & Supply Chain Management
- 2020-2022 TRP Observations Report

### October – December 2022
- Applicant Handbook
- Model Full Review TB/HIV FR
- Model Malaria Prioritization Table
- Frequently Asked Questions (Updated)
- Updated Co-Financing Commitment Letter
- 15 additional Technical Briefs & Guidance Notes covering Community, Human Rights, Gender, Sustainability, Transition, Co-Financing, and more
- Revised OPN on Design and Review of Funding Requests

### Early 2023
- Funding Request Tracker
- Matching Funds Tracker
- Country Information Tool (pulling key info on allocations, grants, and funding request development into one accessible place)
## Webinars

<table>
<thead>
<tr>
<th>Session</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overview: Applying for Funding in 2023-2025</td>
<td>22 September</td>
</tr>
<tr>
<td>Country Dialogue Expectations Including Program Split</td>
<td>5 October</td>
</tr>
<tr>
<td>High-Impact &amp; Core Portfolios: Applying with the Full Review and Program Continuation Application Approaches*</td>
<td>25 October</td>
</tr>
<tr>
<td>Focused Portfolios: Applying with the Tailored for Focused and Transition Application Approaches*</td>
<td>2 November</td>
</tr>
<tr>
<td>Applying with the Tailored for National Strategic Plans Application Approach*</td>
<td>9 November</td>
</tr>
<tr>
<td>Updates to Information Notes including Program Essentials and RSSH Critical Approaches</td>
<td>24 November</td>
</tr>
<tr>
<td>Sustainability, Transition and Co-financing and Innovative Financing</td>
<td>30 November</td>
</tr>
<tr>
<td>Allocations: Overall Outcome</td>
<td>7 December</td>
</tr>
<tr>
<td>Matching Funds</td>
<td>13 December</td>
</tr>
</tbody>
</table>

* Includes overview of the Forms, Instructions and Annexes

Interpretation of the webinars and translated slides will be offered in French and Spanish (and later available on iLearn).